Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 2Psoriasis 1Prostatic Neoplasms 1Precancerous Conditions 1Osteoarthritis 1Neoplasm, Residual 1Multiple Sclerosis 1Healthy Subject 1Cardiovascular Diseases 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms, Male 1Breast Neoplasms 1Breast Carcinoma In Situ 1Autoimmune Diseases 1Arthritis, Rheumatoid 1Aggressive Periodontitis 1

Interventions

Tamoxifen 9Letrozole 5Anastrozole 5Radiotherapy 3Radiation 3Neoadjuvant Therapy 3afimoxifene 2Trastuzumab 2Surgical Procedures, Operative 2Simvastatin 2Sentinel Lymph Node Biopsy 2Radiation Dose Hypofractionation 2Mastectomy, Segmental 2Lapatinib 2Gene Expression Profiling 2trastuzumab biosimilar HLX02 1telapristone acetate 1sargramostim 1polyphenon E 1pasireotide 1palbociclib 1oxybutynin 1liposomal doxorubicin 1exemestane 1Zoledronic Acid 1UAB 30 1Tea 1Sugars 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Intraductal, Noninfiltrating × Fish Oils × Clear all
NCT01869764 2019-10-30

Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

Wake Forest University Health Sciences

Phase 2 Completed
57 enrolled 8 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡